Press Releases Latest Apr 15, 2024 Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders Press Releases Year None202420232022202120202019201820172016201520142013 May 10, 2022 Appointments in Conjunction With Theratechnologies Annual Meeting May 10, 2022 Theratechnologies Initiates Basket Portion of TH1902 First-in-Human Study in Advanced Resistant Malignancies Apr 27, 2022 Theratechnologies to Focus Its Commercialization Activities on the North American Territory Apr 25, 2022 Theratechnologies to Present at Bloom Burton & Co. Healthcare Investor Conference 2022 Apr 13, 2022 Theratechnologies Reports Financial Results for First Quarter Fiscal 2022 and Provides Business Update Apr 08, 2022 Theratechnologies Presents New In Vivo TH1902 Preclinical Data Demonstrating Tumor Growth Inhibition of Human Cancer Stem-Like Cells (CD133+) in Both Triple-Negative Breast and Ovarian Cancers AACR Annual Meeting 2022 Mar 31, 2022 Theratechnologies to Announce Financial Results for Its First Quarter 2022 Mar 08, 2022 Theratechnologies to Present Three Posters at AACR Including New In Vivo TH1902 Preclinical Data Demonstrating Tumor Growth Inhibition of Human Cancer Stem-Like Cells (CD133+) in Both Triple-Negative Breast and Ovarian Cancers Feb 24, 2022 Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update Feb 16, 2022 Theratechnologies Presents Results From Trogarzo® IV Push Administration Study at CROI 2022 First page « Previous page ‹ … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page › Last page » Displaying 81 - 90 of 360
Apr 15, 2024 Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
May 10, 2022 Theratechnologies Initiates Basket Portion of TH1902 First-in-Human Study in Advanced Resistant Malignancies
Apr 27, 2022 Theratechnologies to Focus Its Commercialization Activities on the North American Territory
Apr 13, 2022 Theratechnologies Reports Financial Results for First Quarter Fiscal 2022 and Provides Business Update
Apr 08, 2022 Theratechnologies Presents New In Vivo TH1902 Preclinical Data Demonstrating Tumor Growth Inhibition of Human Cancer Stem-Like Cells (CD133+) in Both Triple-Negative Breast and Ovarian Cancers AACR Annual Meeting 2022
Mar 08, 2022 Theratechnologies to Present Three Posters at AACR Including New In Vivo TH1902 Preclinical Data Demonstrating Tumor Growth Inhibition of Human Cancer Stem-Like Cells (CD133+) in Both Triple-Negative Breast and Ovarian Cancers
Feb 24, 2022 Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update
Feb 16, 2022 Theratechnologies Presents Results From Trogarzo® IV Push Administration Study at CROI 2022
